Immatics Final logo (R)_white_background.png
Immatics Announces Pricing of $150 Million Public Offering
10 oct. 2024 20h50 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Final logo (R)_white_background.png
Immatics Announces Proposed $150 Million Public Offering
10 oct. 2024 07h30 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Final logo (R)_white_background.png
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
10 oct. 2024 06h30 HE | https://immatics.com/
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily...
Immatics Final logo (R)_white_background.png
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
04 oct. 2024 09h00 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development...
Immatics Final logo (R)_white_background.png
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
16 sept. 2024 05h25 HE | https://immatics.com/
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on...
Immatics Final logo (R)_white_background.png
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
06 sept. 2024 07h00 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and...
Immatics Final logo (R)_white_background.png
Immatics Announces Second Quarter 2024 Financial Results and Business Update
13 août 2024 07h00 HE | https://immatics.com/
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of...
Immatics Final logo (R)_white_background.png
Immatics Appoints Alise Reicin to Board of Directors
31 juil. 2024 07h00 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...
Immatics Final logo (R)_white_background.png
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
18 juil. 2024 09h00 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Final logo (R)_white_background.png
Immatics Announces First Quarter 2024 Financial Results and Business Update
14 mai 2024 07h00 HE | https://immatics.com/
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily...